ALPS Advisors’s Celldex Therapeutics CLDX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$1.72M Sell
54,190
-369
-0.7% -$10.1K 0.01% 433
2025
Q4
$1.48M Buy
54,559
+22,643
+71% +$596K 0.01% 458
2025
Q3
$826K Sell
31,916
-3,896
-11% -$90.3K ﹤0.01% 590
2025
Q2
$729K Sell
35,812
-14,126
-28% -$275K ﹤0.01% 579
2025
Q1
$906K Sell
49,938
-3,712
-7% -$82.9K 0.01% 485
2024
Q4
$1.36M Buy
53,650
+2,993
+6% +$81.3K 0.01% 410
2024
Q3
$1.72M Sell
50,657
-742
-1% -$28.3K 0.01% 383
2024
Q2
$1.9M Buy
51,399
+5,959
+13% +$225K 0.01% 346
2024
Q1
$1.91M Buy
45,440
+7,795
+21% +$320K 0.01% 359
2023
Q4
$1.49M Buy
37,645
+2,797
+8% +$82.3K 0.01% 383
2023
Q3
$959K Buy
34,848
+113
+0.3% +$3.54K 0.01% 465
2023
Q2
$1.18M Buy
34,735
+3,630
+12% +$122K 0.01% 437
2023
Q1
$1.12M Sell
31,105
-844
-3% -$36.4K 0.01% 446
2022
Q4
$1.42M Buy
31,949
+6,389
+25% +$228K 0.01% 368
2022
Q3
$718K Sell
25,560
-2,180
-8% -$66.8K 0.01% 536
2022
Q2
$748K Buy
+27,740
New +$806K 0.01% 517
2021
Q2
Sell
-71,581
Closed -$1.48M 906
2021
Q1
$1.48M Buy
71,581
+861
+1% +$19.8K 0.01% 353
2020
Q4
$1.24M Buy
+70,720
New +$1.27M 0.01% 366
2017
Q2
Sell
-7,013
Closed -$380K 773
2017
Q1
$380K Buy
7,013
+526
+8% +$27.4K ﹤0.01% 671
2016
Q4
$344K Sell
6,487
-2,058
-24% -$117K ﹤0.01% 655
2016
Q3
$518K Sell
8,545
-700
-8% -$43.6K ﹤0.01% 265
2016
Q2
$609K Buy
9,245
+1,845
+25% +$117K 0.01% 229
2016
Q1
$420K Sell
7,400
-1,263
-15% -$142K ﹤0.01% 531
2015
Q4
$2.04M Sell
8,663
-1,613
-16% -$352K 0.02% 177
2015
Q3
$16.2K Buy
10,276
+3,761
+58% +$1.06M 0.02% 183
2015
Q2
$2.46M Buy
6,515
+3,305
+103% +$1.31M 0.02% 152
2015
Q1
$1.34M Buy
+3,210
New +$1.15M 0.01% 170

Other funds holding CLDX